Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Condition(s):Advanced Adult Hepatocellular CarcinomaLast Updated:August 23, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Advanced Adult Hepatocellular CarcinomaLast Updated:August 23, 2016Completed
Condition(s):GlioblastomaLast Updated:February 24, 2017Withdrawn
Condition(s):Clear Cell Renal Cell CarcinomaLast Updated:February 24, 2017Completed
Condition(s):Glioblastoma MultiformeLast Updated:February 24, 2017Completed
Condition(s):Prostatic NeoplasmsLast Updated:February 24, 2017Completed
Condition(s):Prostate Cancer.Last Updated:February 19, 2014Withdrawn
Condition(s):Advanced Solid TumorsLast Updated:December 10, 2015Completed
Condition(s):Hepatocellular CarcinomaLast Updated:March 10, 2014No longer available
Condition(s):Metastatic Gastric CancerLast Updated:January 29, 2016Unknown status
Condition(s):Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular DiseaseLast Updated:September 22, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.